Is Stem Cell Therapy Abroad Safe? Risks & Red Flags

Is Stem Cell Therapy Abroad Safe? The Short Answer

Yes — but with an important caveat. Across 62 randomized trials in 3,546 patients, mesenchymal stem cell (MSC) therapy caused no rise in serious adverse events such as death or infection. The danger in going abroad usually comes not from the cells, but from unregulated clinics with no quality control.

That distinction is the most useful thing you can carry into this decision. When safety data is gathered carefully, the picture is reassuring. A 2021 meta-analysis of 62 randomized controlled trials, published in Stem Cell Research & Therapy, found no excess of serious adverse events versus control across roughly 20 diseases (Wang, Yi & Song, 2021). This is high-certainty evidence, because it pools many randomized trials rather than a handful of cases.

So why do the headlines tell a darker story? Because the worst outcomes almost always trace back to where and how the treatment was delivered — not to the cells. The rest of this guide separates those two questions, so you can judge any clinic, in any country, on the things that actually move the risk.

What Are the Real Risks of Stem Cell Tourism?

Stem cell tourism means traveling abroad for treatments that are unproven, unapproved, or unregulated at home. The documented stem cell tourism risks include infection, tumors, blood clots, vision loss, and — because care ends when you fly home — having no one nearby to manage complications.

These are not hypothetical. The most cited example was published in the New England Journal of Medicine: three women suffered severe, permanent vision loss after a US “stem-cell clinic” injected autologous (your-own) adipose-derived cells directly into their eyes for macular degeneration, reported in NEJM (Kuriyan et al., 2017). Their vision fell from roughly 20/30–20/200 before the procedure to between 20/200 and no light perception within a year.

Read that case carefully, because it makes the central point of this article. The cells used were adipose-derived — the same broad family of cells used in regulated clinics. What caused the harm was the setting: an unproven indication, an unsafe route of injection (intravitreal — into the eye), and no meaningful quality control. The lesson is not “avoid stem cells.” It is “avoid unregulated stem cell delivery.”

Is the Therapy Itself Risky — or the Setting?

It is mostly the setting. In regulated trials, mesenchymal stem cells are well tolerated, with mostly mild, short-lived effects. Severe harm tends to appear where cells are given by the wrong route, in the wrong dose, without sterility testing — not because stem cells are inherently dangerous.

The same 62-trial meta-analysis in Stem Cell Research & Therapy is reassuring here. It found no increase in death or infection, and the events that did occur were largely transient — a short-lived, low-grade fever, for instance, was more common after treatment than in control groups (Wang, Yi & Song, 2021). In plain terms: most side effects are mild and pass within days.

Contrast that with the eye-injury cases above. Same cell family, completely different outcome — driven by route, dose, and the absence of a regulated process. That is the honest takeaway, and it cuts both ways: stem cell therapy is not a miracle, and it is not a cure, but in a properly regulated setting its safety profile is well documented.

Who should be cautious, and what to expect. Stem cell therapy is generally not appropriate for people with active cancer or an active infection, and every reputable physician will screen for these. Expected side effects are usually limited to mild fever, soreness at the fat-harvest or injection site, and temporary swelling. Serious adverse events are rare in regulated settings — but no medical treatment is risk-free, results vary by individual, and outcomes depend on disease stage and protocol. Any decision should be made with a qualified physician.

Why Some Overseas Clinics Are Risky: The Regulation Gap

In countries like Mexico and Thailand, stem cell treatment often sits in a legal grey area with limited government oversight. Clinics may use cells of unknown source, purity, or dose, with little mandatory testing — which is what turns an otherwise promising therapy into a real safety risk.

The problem is rarely the country’s doctors; it is the absence of binding rules. Where no law requires a government-certified processing lab, batch sterility testing, or a filed treatment plan, the burden of judging quality falls entirely on you — the patient. Therefore the key question to ask is not “Is this country famous for stem cells?” but “What, specifically, is this provider required to do before treating me?”

This is also why price comparisons can mislead. A very low quote often reflects a process with fewer cells and fewer checks, not simply a cheaper version of the same product.

How Stem Cell Regulation Differs by Country

Stem cell regulation varies enormously by country: Japan has a dedicated national law, the United States restricts cultured cells to clinical trials, and Mexico and Thailand operate with limited oversight. The single biggest safety variable is whether a specific law and mandatory quality testing exist.

Rather than rank countries by price, the table below compares them on the factors that actually protect you. (For a full cost-and-process breakdown of treatment in Japan specifically, see the Japan guide linked further down.)

As the table shows, Japan is among the few markets where private-clinic regenerative medicine is governed by a dedicated law with a certified lab and mandatory testing. In most other destinations, those safeguards are optional — which is precisely where the safety gap opens.

Japan vs. Mexico vs. Thailand: A Safety-First View

On safety, the Japan vs. Mexico contrast is concrete. Japan requires a government-filed treatment plan, a certified processing lab, and batch testing before any infusion; many lower-cost destinations require none of these. Cultured doses in Japan typically reach 100–200 million tested cells, versus often under 10 million in same-day procedures.

None of this means good care is impossible in Mexico or Thailand — careful, ethical clinics exist in many countries. It means the floor is different. In Japan, the law sets a minimum standard every clinic must clear; elsewhere, the standard depends almost entirely on the individual clinic you happen to choose. For a patient comparing options from abroad, a dependable floor is worth a great deal.

If your main question is cost and logistics rather than regulation, the dedicated Japan guide breaks down pricing, visits, and the full treatment process step by step.

Stem Cell Therapy in Japan: Cost, Safety & What to Expect
Read Guide

Cultured vs. Same-Day Cells: Why Dose and Sterility Matter

The difference between cultured and same-day stem cells is large. Same-day procedures inject cells within hours, often delivering under 10 million with minimal testing. A 7-week cultured process expands cells to 100–200 million and screens them for bacteria, mycoplasma, and viability before release.

Dose and source are not marketing details — they show up in outcomes. A 2025 meta-analysis of 8 randomized trials in 502 patients with unoperated knee osteoarthritis, published in Stem Cell Research & Therapy, found that intra-articular (into-the-joint) MSC injection improved WOMAC scores — a standard symptom-and-function index, where lower is better — by a mean of 7.44 points at 6 months and 10.31 points at 12 months versus control, with adverse events no different from the control group (Cao et al., 2025). Crucially, the subgroup analysis showed that adipose-derived cells and higher doses produced the strongest results.

That is a high-certainty signal, because it pools randomized trials. It also tells you what to look for: WOMAC is a symptom measure rather than proof of regrown cartilage, so honest clinics describe benefits as improved pain and function — and they invest in the dose and culture quality that the data rewards. A same-day shot of a few million untested cells is simply not the same product.

How to Vet Any Stem Cell Clinic Before You Travel

Before you travel, judge the provider, not the country. To choose a stem cell clinic wisely, ask five things: the legal plan or approval number, who processes the cells and where, the cell count and culture time, the physician’s regenerative-medicine credentials, and the published evidence behind your specific treatment.

A clinic that answers all five clearly is signalling that it operates inside a real quality system. Vague or evasive answers are themselves the red flag.

Does “Cheaper Abroad” Mean Riskier?

Not automatically — but a very low price for stem cell therapy abroad often signals fewer cells, less testing, and lighter oversight. Cheaper same-day procedures can cost a fraction of cultured therapy, yet deliver a fraction of the dose. Compare what is actually included, not just the headline number.

A useful habit is to convert price into “cost per tested cell, under regulation.” Seen that way, the cheapest option is sometimes the most expensive — because a treatment that delivers too few cells, or causes a complication far from home, can cost far more than it saved. Cost has its place in the decision; it just should not be the first filter. Regulation should be.

Why Cell Grand Clinic in Japan

Cell Grand Clinic is built around the safety variables that matter abroad: MHLW Type 2 certification, a certified processing lab, and individually cultured adipose-derived stem cells — never donor-pooled. Treatment is led end to end by Dr. Yuichi Wakabayashi, a NIH-trained, ABRM-board-certified physician with over 3,000 cases.

Cell Grand Clinic operates under Japan’s Act on the Safety of Regenerative Medicine as an MHLW Type 2–certified provider — a higher-tier risk classification within the Act, applicable to treatments using cultured autologous cells. Every dose is produced through the Grand Stem Cell quality process, designed around four standards:

• Cultured Exclusively for You. No off-the-shelf or pooled stock. After treatment is decided, your cells are cultured over 7 weeks from your own minimal fat tissue — each batch for one patient only.
• ISCT-Standard Verification. Surface-marker testing follows International Society for Cell & Gene Therapy (ISCT) standards to confirm the cells are genuine mesenchymal stem cells; cells that fall short are discarded.
• 95%+ Viability — Only Living Cells. Viability is confirmed up to the moment of administration, because dead or degraded cells do not aid repair.
• Youth and Volume, Without Compromise. Cells are kept at Passage 3 or below to preserve regenerative capacity, while still reaching up to 200 million cells. Every patient receives a Certificate of Quality documenting that their Grand Stem Cells met all four standards.

Because the same physician handles your case from first inquiry through evaluation, harvesting, administration, and 6- and 12-month follow-up, there is no care-continuity gap of the kind that makes treatment abroad risky. Cell Grand Clinic also offers exosome and NMN options as cell-free or supportive protocols — and a 2024 systematic review of 21 clinical reports of extracellular-vesicle (exosome) therapy, published in the Journal of Extracellular Vesicles, reported a serious-adverse-event rate of just 0.7% (95% CI 0.1–5.2%), though the authors note that manufacturing and reporting still vary widely (Van Delen et al., 2024).

To go deeper on two of the factors above, see the detailed quality-lab explainer and, for the knee-specific evidence many readers ask about, the dedicated knee osteoarthritis guide.

Cell Quality: The Factor That Most Affects Stem Cell Therapy Outcomes
Learn More


Knee Osteoarthritis: A Non-Surgical Path With Stem Cells
Read Article

Frequently Asked Questions

Has anyone been seriously harmed by stem cell tourism?

Yes. The most cited case, in the New England Journal of Medicine (2017), described three women who suffered severe, permanent vision loss after a US clinic injected adipose-derived “stem cells” into their eyes. The harm came from an unsafe route and no quality control — not from stem cells as a category.

Is stem cell therapy approved by the FDA?

In the United States, the FDA currently limits cultured (laboratory-expanded) stem cell therapies to clinical trials, so they are not offered as routine treatment there. In Japan, the same cultured therapies are permitted and regulated under the Act on the Safety of Regenerative Medicine, overseen by the MHLW.

Is stem cell therapy in Mexico safe?

It depends entirely on the specific clinic. Mexico has no dedicated national law for clinic-based regenerative medicine, so safeguards like certified processing labs and mandatory testing are not assured. Some clinics are careful; others are not — which is why vetting the provider matters more than the country.

Which country is the safest for stem cell therapy?

On structural safety, the safest option is a country with a dedicated law plus mandatory quality testing — Japan being the clearest example for private-clinic regenerative medicine. A specific law, a certified processing lab, and batch testing are the variables that most reduce risk.

What happens if something goes wrong after treatment abroad?

This is a real weakness of stem cell tourism. Once you fly home, the treating clinic is far away, and your local doctors may not have records of what was administered. Continuity of care — follow-up at defined intervals and accessible records — is one of the clearest markers of a responsible provider.

Considering Stem Cell Therapy? Speak With Dr. Wakabayashi Directly.

Choosing a regenerative medicine clinic — especially across borders — is a decision that deserves a real conversation, not a sales pitch.

Cell Grand Clinic offers direct physician consultation before any commitment. You’ll speak with Dr. Yuichi Wakabayashi, M.D., Ph.D., NIH-trained, ABRM-certified, with over 3,000 stem cell treatments completed.

During your consultation, Dr. Wakabayashi will:

• Review your medical records and current treatments
• Explain whether your specific case is likely to respond to stem cell therapy
• Outline expected outcomes for your condition — and say clearly when stem cells are not the right option
• Provide a written treatment plan with all costs disclosed upfront

Available in: English · Japanese · Mandarin
Response time: Within 24 hours
Consultation fee: None
Follow-up calls: Only if you request them

All inquiries are reviewed under medical confidentiality. We do not share patient information with third parties.

References

1. Wang Y, Yi H, Song Y. The safety of MSC therapy over the past 15 years: a meta-analysis. Stem Cell Res Ther. 2021;12(1):545. https://doi.org/10.1186/s13287-021-02609-x
2. Kuriyan AE, Albini TA, Townsend JH, et al. Vision loss after intravitreal injection of autologous “stem cells” for AMD. N Engl J Med. 2017;376(11):1047-1053. https://doi.org/10.1056/NEJMoa1609583
3. Cao M, Ou Z, Sheng R, et al. Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2025;16(1):122. https://doi.org/10.1186/s13287-025-04252-2
4. Van Delen M, Derdelinckx J, Wouters K, Nelissen I, Cools N. A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J Extracell Vesicles. 2024;13(7):e12458. https://doi.org/10.1002/jev2.12458

Medically reviewed by Yuichi Wakabayashi, MD, PhD — Board-certified regenerative medicine physician (ABRM), Cell Grand Clinic, Osaka, Japan.
Last reviewed: 2026-06-11

Updated: 2026.06.12